Global Immunology Partnering 2015-2022: Deal trends, players and financials
The Global Immunology Partnering 2015-2022: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the immunology partnering deals and agreements entered into by the worlds leading healthcare companies.
Global Immunology Partnering 2015 to 2022 provides the full collection of Immunology disease deals signed between the world’s pharmaceutical and biotechnology companies since 2015.
- Trends in Immunology partnering deals
- Financial deal terms for headline, upfront and royalty by stage of development
- Immunology partnering agreement structure
- Immunology partnering contract documents
- Top Immunology deals by value
- Most active Immunology dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Immunology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Immunology deals.
The report presents financial deal terms values for Immunology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Immunology dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Immunology dealmaking since 2015 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Immunology deals since 2015. Deals are listed by headline value. The chapter includes the top 25 most active Immunology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Immunology deals since 2015 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Immunology partnering deals by specific Immunology target announced since 2015. The chapter is organized by specific Immunology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Immunology partnering deals signed and announced since 2015. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Immunology partnering and dealmaking since 2015.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Immunology technologies and products.
Global Immunology Partnering 2015 to 2022 is intended to provide the reader with an in-depth understanding and access to Immunology trends and structure of deals entered into by leading companies worldwide.
Global Immunology Partnering 2015 to 2022 includes:
- Trends in Immunology dealmaking in the biopharma industry since 2015
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Immunology deal contract documents
- Comprehensive access to over 950 Immunology deal records
- The leading Immunology deals by value since 2015
- Most active Immunology dealmakers since 2015
The report includes deals for the following indications: AIDS, Allergy, Anaphylactic shock, Graft versus host disease, Inflammation, Other autoimmune, Scleroderma, Systemic lupus erythematosus, plus other immunology indications.
In Global Immunology Partnering 2015 to 2022, available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Immunology Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 950 immunology deals. Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are the sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Global Immunology Partnering 2015 to 2022 provides the reader with the following key benefits:
- In-depth understanding of Immunology deal trends since 2015
- Access Immunology deal headline, upfront, milestone and royalty data
- Research hundreds of actual contracts between Immunology partner companies
- Comprehensive access to over 950 links to actual Immunology deals entered into by the world’s biopharma companies
- Indepth review of Immunology deals entered into by the top 25 most active dealmakers
- Benchmark the key deal terms companies have agreed in previous deals
- Identify key terms under which companies partner Immunology opportunities
- Uncover companies actively partnering Immunology opportunities
Chapter 1 – Introduction
Chapter 2 – Trends in Immunology dealmaking
2.2. Immunology partnering over the years
2.3. Immunology partnering by deal type
2.4. Immunology partnering by industry sector
2.5. Immunology partnering by stage of development
2.6. Immunology partnering by technology type
2.7. Immunology partnering by therapeutic indication
Chapter 3 –Financial deal terms for Immunology partnering
3.2. Disclosed financials terms for Immunology partnering
3.3. Immunology partnering headline values
3.4. Immunology deal upfront payments
3.5. Immunology deal milestone payments
3.6. Immunology royalty rates
Chapter 4 – Leading Immunology deals and dealmakers
4.2. Most active in Immunology partnering
4.3. List of most active dealmakers in Immunology
4.4. Top Immunology deals by value
Chapter 5 – Immunology contract document directory
5.2. Immunology partnering deals where contract document available
Chapter 6 – Immunology dealmaking by therapeutic target
6.2. Deals by Immunology therapeutic target
Appendix 1 – Directory of Immunology deals by company A-Z since 2015
Appendix 2 – Directory of Immunology deals by deal type since 2015
Appendix 3 – Directory of Immunology deals by stage of development since 2015
Appendix 4 – Directory of Immunology deals by technology type since 2015
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Recent report titles from CurrentPartnering
Table of figures
Figure 1: Immunology partnering since 2015
Figure 2: Immunology partnering by deal type since 2015
Figure 3: Immunology partnering by industry sector since 2015
Figure 4: Immunology partnering by stage of development since 2015
Figure 5: Immunology partnering by technology type since 2015
Figure 6: Immunology partnering by indication since 2015
Figure 7: Immunology deals with a headline value
Figure 8: Immunology deals with upfront payment values
Figure 9: Immunology deals with milestone payment
Figure 10: Immunology deals with royalty rates
Figure 11: Active Immunology dealmaking activity since 2015
Figure 12: Top Immunology deals by value since 2015
- $3,495: single-user
- $5,245: multi-user
- $10,495: single site license
- $17,495: global site license
A full explanation of license type definitions can be found here.
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
All card payments are processed by SagePay.
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
3SBio, 4C Biomed, 4D Pharma, 4SC, 7 Hills Pharma, 9 Meters Biopharma, 23andMe, A*STAR Agency for Science, Technology and Research, A*STAR Genome Institute of Singapore, A*STAR’ Institute of Molecular and Cell Biology, Aarhus University Hospital, Aavis Pharmaceuticals, AB2 Bio, Abarca, AB Biosciences, Abbott Laboratories, Abbvie, Abcam, AbCellera, Abcuro, Abdul Latif Jameel Health, Abexxa Biologics, Abingworth Management, ABL Bio, Ablynx, Abpro, Abreos Biosciences, AbSci, ABVC BioPharma, Abveris, Abzena, Acelyrin, Acerta Pharma, Aceso Life Science, Acetylon Pharmaceuticals, AC Immune, Actelion, Acucela, Acuitas Therapeutics, AdAlta, Adamis Pharmaceuticals, Adaptate Biotherapeutics, Adaptive Biotechnologies, Adicet Bio, Aditx Therapeutics, Aduro BioTech, Advanz Pharma, Advaxis, Aevi Genomic Medicine, Aevitas Therapeutics, Affibody, AffyXell Therapeutics, AGC Biologics, Agenus Bio, AgomAb Therapeutics, AHN Autoimmunity Institute, AiCuris, AIDS Clinical Trials Group, AIDS Foundation Houston, AIDS Foundation of Chicago, Aimmune Therapeutics, Ajinomoto, Akers Biosciences, Akeso Biopharma, Akoya Biosciences, Akrevia Therapeutics, Akriveia Therapeutics, Alder Biopharmaceuticals, Aldeyra Therapeutics, Alector, Alexion Pharmaceuticals, ALK-Abello, Allakos, Allegheny General Hospital, AllerGenis, Alliance for Lupus Research, Allied-Bristol Life Sciences, Alloksys Life Sciences, Alloy Therapeutics, Almirall, Alpha Cancer Technologies, Alpine Immune Sciences, AltaVoice, Alvotech, Alyatec, AM-Pharma, Amagma Therapeutics, Amal Therapeutics, Amegabiotech, American Type Culture Collection (ATCC), Amgen, AMPEL BioSolutions, Amphista Therapeutics, Ampio Pharmaceuticals, Amplyx Pharmaceuticals, Amunix, AnaMar, Anelixis Therapeutics, Anergis, Angany, ANI Pharmaceuticals, Annapurna Therapeutics, Anokion, Anpac Bio-Medical Science, Antibe Therapeutics, AntibioTx, Antisoma Therapeutics, Apeiron Biologics, Apellis Pharmaceuticals, Apocell, Applied BioMath, Applied Cells, AprilBio, Aptahem, Aptar Pharma, Aptevo Therapeutics, Aptorum Group, Aqemia, Aqilion, Aquila BioMedical, Aralez Pharmaceuticals, Aratana Therapeutics, aratinga.bio SAS Group, Arbele, Arbutus, Archer Daniels Midland Company, ArcherDX, Arcutis Biotherapeutics, Arena Pharmaceuticals, arGEN-X, argenx, Argonne National Laboratory, Aristea Therapeutics, Armas Pharmaceuticals, Array Biopharma, Arrien Pharmaceuticals, ARS Pharmaceuticals, Artelo Biosciences, Artisan Bio, Artizan Biosciences, Asahi Kasei, AskAt, Aslan Pharma, Assertio Therapeutics, Astellas Pharma, Astion Pharma, AstraZeneca, Atara Biotherapeutics, ATGen Global, Atomwise, Atreca, Aurinia Pharmaceuticals, Australian Research Council, Avacta, Avactis Biosciences, Avalere Health, Avalon GloboCare, Avectas, Aviceda Therapeutics, Avid Bioservices, Avidea Technologies, Avidity Biosciences, Avillion, Avrobio, Axcelead Drug Discovery Partners, Axela, AyoxxA Biosystems, Bausch & Lomb, Baxalta, Baxter International, Bayer, Bayer Animal Health, B Braun, BCD Bioscience, Beacon Discovery, Beactica, Beckman Coulter, BeiGene, Beijing InnoCare Pharma, Beijing Wonner Biotech, Beijing Yuan Jian Health Management, Benaroya Research Institute, BenevolentAI, Berg, Berkeley Lights, Bertin Pharma, Be The Match BioTherapies, Beth Israel Deaconess Medical Center, Bial, Bicycle Therapeutics, Bill and Melinda Gates Foundation, Bina Technologies, Bio-Cancer Treatment International, Bio-Me, Bio-Path, Bio-Techne, BioAge Labs, BioAgilytix, BioBright, Biocartis, Bioceros, Biocon, BioCopy, bioCSL, Biocytogen, BioDuro, Biogen, Biohaven Pharmaceuticals, BioInvent, BioKey, Biokinesis, BiologicTx, Biolojic Design, Biomedical Advanced Research and Development Authority, BioMed X Innovation Center, Biomunex Pharmaceuticals, Bioniz Therapeutics, BioNova Pharmaceuticals, Bioqube Ventures, BioRap Technologies, BiosanaPharma, BioSense Global, BioSight, Biosortia Pharmaceuticals, Biotest, Biotest Pharmaceuticals, BirchBioMed, Black AIDS Institute, Blacksmith Medicines, Bleeding Disorders Foundation, Bloom Science, BlueRock Therapeutics, BlueWillow Biologics, Boehringer Ingelheim, Boston Pharmaceuticals, Botanisol, Bpifrance, Brickell Biotech, Bridge Biotherapeutics, Brigham and Women's Hospital, Bright Peak Therapeutics, Brii Biosciences, Bristol-Myers Squibb, Broad Institute, Bruker, Bryn Pharma, Bukwang Pharmaceuticals, BullFrog AI, C4X Discovery, Cabaletta Bio, Caelum Biosciences, Caladrius Biosciences, California Institute for Regenerative Medicine, Calliditas Therapeutics, Calypso Biotech, Cambridge Enterprise, Camurus, Canadian Council, CANbridge Pharmaceuticals, Cancer Genetics, Cancer Research Institute, Cannvalate, Canopy Biosciences, Cantargia, Capella Bioscience, Carbiotix, CareFirst BlueCross BlueShield, Carna BioSciences, Casebia Therapeutics, Catalyst Pharmaceuticals, CB2 Therapeutics, Celgene, Cellectis, Cellgen Diagnostics, Cell Mogrify, CellSight Technologies, Cend Therapeutics, Center for iPS Cells Research and Application, Centers for Disease Control and Prevention, Centessa Pharmaceuticals, Centogene, Central Institute for Experimental Animals, Centre Leon Berard, Centurion, Century Therapeutics, Cerecor, Changchun High & New Technology Industries, Charite Universitatsmedizin Berlin, Charles River Laboratories, Checkpoint Therapeutics, ChemoCentryx, Cheplapharm Arzneimittel, Chi-Med, Children's Hospital Boston, Children's Hospital of Philadelphia, Chong Kun Dang, Chr Hansen, ChromaDex, Chromocell, Chugai Pharmaceutical, Chugai Pharma Marketing, Cigna Healthcare, Cincinnati Children’s Hospital Medical Center, Cipher Pharmaceuticals, Cipla, Circassia, Circuit Clinical, Circulogene, City of Hope, Clinical Ink, Clinigen, CMS Medical, Cogen Immune Medicines, Coherus Biosciences, CoImmune, COI Pharmaceuticals, Columbia University, Commense, Compass Therapeutics, Complix, Compugen, ConsortiaTX, Corbin Therapeutics, Corbus Pharmaceuticals, Corden Pharma, CoreRx Pharma, Cornell University, Corrona, Courier Therapeutics, COUR Pharmaceutical, COVAXX, Coya Therapeutics, Crescendo Biologics, CRISPR Therapeutics, Cristal Therapeutics, Cromos Pharma, Crown Bioscience, Cryostem, Crystal Bioscience, CSL Behring, CSL Plasma, CSPC Pharmaceutical Group, Cue Biopharma, Cullinan Oncology, Curable, Curadev Pharma, Curetis, CureVac, Curzion Pharmaceuticals, Cyclacel Pharmaceuticals, Cyclenium Pharma, Cyclofluidic, CyDex, Cygnus, Cynata Therapeutics, Cyntar Ventures, Cynvenio, Cyrus Biotechnology, Cystic Fibrosis Foundation Therapeutics, CytoAgents, Cytobank, Cytocom, CytoLynx Therapeutics, CytomX Therapeutics, CytoReason, Cytori Therapeutics, CytoSen Therapeutics, CytoSorbents, Cytovance Biologics, CYTOVIA Therapeutics, Daewoong Pharmaceutical, Daiichi Sankyo, Dako, Dalhousie University, Dana-Farber Cancer Institute, DAS Therapeutics, DBV Technologies, Defense Advanced Research Projects Agency, Denali Therapeutics, DendroCyte, Department of Defense, Dermira, Devonian Health Group, DiaCarta, Diaccurate, Diamyd Medical, Dianomi Therapeutics, Diatheva, DKSH, DNAtrix, DNX Biopharmaceuticals, Dong-A ST, Dr. Reddy's Laboratories, Dragonfly Therapeutics, Dualogics, Duke University, DyDo Pharma, Edesa Biotech, EdiGene, Egle Therapeutics, Eisai, Eisai Inc, Eli Lilly, Elpis Biomed, ElsaLys Biotech, Elton John AIDS Foundation, EMD Serono, Emerge Health, Emory University, Enable Biosciences, Enamine, EnBiotix, Enesi Pharma, Ensemble Therapeutics, Enterome Bioscience, Entos Pharmaceuticals, Enumeral Biomedical, Enzychem Lifesciences, EOM Pharmaceuticals, EpimAb Biotherapeutics, Epirus Biopharmaceuticals, Epiva Biosciences, Epivax, EQRx, Equillium, Erasmus University Medical Center, Escient Pharmaceuticals, Essex Bio-Technology, eTheRNA immunotherapies, Eton Pharmaceuticals, Eurofins Discovery, Eurofins Scientific, European Innovation Council, European Union, Eutilex, Evelo Biosciences, Everest Medicines, Evidation Health, Evommune, EVOQ Therapeutics, Evotec, Ewopharma, Exagen Diagnostics, ExeGi Pharma, Expedeon, ExScientia, F-Star, F-Star Therapeutics, Fairhaven Pharmaceuticals, FairJourney Biologics, Federal Ministry of Health (Germany), Feinstein Institute for Medical Research, Feldan Therapeutics, Ferring Pharmaceuticals, Fibrocell Science, Fibrogen, Fidelta, Five Prime Therapeutics, Fluo Labs, Folia Biotech, Food Allergy Research & Education, Food and Drug Administration (FDA), Forge Biologics, Forge Therapeutics, Fortress Biotech, Foundation Medicine, Foundery Innovations, Fred Hutchinson Cancer Research Center, French National Institute for Agricultural Research, Fresenius Kabi Pharmaceuticals, FSD Pharma, Fujifilm, Fuji Pharma, Fundacion Progreso y Salud, Galapagos, Galecto, GammaDelta Therapeutics, Gateway Hemophilia Association, GC LabCell, GE Healthcare, GEMoaB, Gencia Biotech, Genentech, GeneQuantum Healthcare, Genethon, Genfit, Genmab, Genomic Testing Cooperative, Genovis, GenScript Biotech, GentiBio, Georgetown University, George Washington University, GeoVax, Gesynta Pharma, Gilead Sciences, Ginkgo BioWorks, GlaxoSmithKline, Glenmark Pharmaceuticals, Global Centers for Therapeutic Innovation, Global Stem Cell Technology, GlycoT Therapeutics, Gores Group, Gossamer Bio, Gradalis, Graphite Bio, Great Ormond Street Hospital (GOSH), Gritstone Bio, Grunenthal, GT Biopharma, Guardant Health, Guojian Pharma, Hadasit Medical Research Services and Development, HalioDx, Halozyme Therapeutics, Hamilton Company, HanAll Pharmaceuticals, Hangzhou Zhongmei Huadong Pharmaceutical, Hanmi Pharmaceutical, Hannover Medical School, Hansa Biopharma, Harbour Biomed, Harvard University, Heat Biologics, Hebrew University of Jerusalem, HemispheRx Biopharma, Hemophilia Foundation of Southern California, Henlius Biotech, HiFiBio, Highline Therapeutics, Hikma Pharmaceuticals, HitGen, Hob Diagnostics, Hoffmann La Roche, Hookipa Pharma, Horizon Pharma plc, Horizon Therapeutics, Hospira, Hospital for Special Surgery, Hoth Therapeutics, Huadong Medicine, Hualan Genetic, Humanigen, Hybridize Therapeutics, I-mab, Icahn School of Medicine at Mount Sinai, IcanoMAB, Ichnos Sciences, ICM, IDIS Pharma, Idorsia, IFM Due, IFM Therapeutics, IFM Tre, Igenica, IGM Biosciences, ILTOO Pharma, ImaginAb, Imbrium Therapeutics, ImCheck Therapeutics, Imcyse, IMIDomics, Immatics Biotechnologies, Immatics US, ImmPACT Bio, Immugenyx, ImmunArray, Immune Deficiency Foundation, Immuneed, ImmuneID, Immune Pharmaceuticals, ImmuNext, Immunic, ImmunoCellular Therapeutics, ImmunoChina Pharmaceuticals, ImmunoFlex, Immunogenesis, Immunomedics, Immunomic, Immunovia, Immunscape, ImmuPharma, Imperial College London, ImQuest Life Sciences, In4Derm, INBRAIN Neuroelectronics, IncellDx, Incyte, Indapta Therapeutics, Indee Labs, InDex Pharmaceuticals, Indigo Biosciences, Indipharm, Infinity Pharmaceuticals, InflamaCORE, Inflazome, Inmagene Biopharmaceuticals, InMed Pharmaceuticals, Innate Pharma, INNERVIA Bioelectronics, Innovate UK, Innovative Genomics Initiative (IGI), Innovative Targeting Solutions, Innovent Biologics, Innovus Pharmaceuticals, Inotrem, Inovalon, Inovio Pharmaceuticals, Inserm Transfert, Inspirotec, Institut Curie, Institute for Basic Science, Institute for Bioscience and Biotechnology Research, Institute for Research in Immunology and Cancer – Commercialization of Research, Institute for the Promotion of Innovation by Science and Technology in Flanders, Institute of Child Health, Institute of Human Virology, Institut Pasteur, Institut Pasteur of Shanghai at the Chinese Academy of Sciences, Intarcia Therapeutics, Integral Molecular, Integrated BioTherapeutics, Intellia Therapeutics, Intellikine, International AIDS Vaccine Initiative, Intrexon, Intrommune Therapeutics, InveniAI, Invitae, iOncologi, Ionis Pharmaceuticals, IONTAS, IP Biotech, IPM Biotech, IQVIA, iReceptor Plus, Ironwood Pharmaceuticals, ISA Scientific, ISD Immunotech, IsoPlexis, Israeli National Authority for Technological Innovation, iTeos Therapeutics, Itus, J-Network, Jacobio Pharmaceuticals, JAGUAHR Therapeutics, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Janssen Therapeutics, Janus Pharmaceuticals, Japan Tobacco, Jasper Therapeutics, Jazz Pharmaceuticals, JDP Therapeutics, Jeffrey Modell Foundation, Jiangsu Chia Tai Tianqing Pharmaceutical, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Medicine, Jiangsu QYuns Therapeutics, Jnana Therapeutics, Johns Hopkins Kimmel Cancer Center, Johns Hopkins Medicine (JHM), Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, Jubilant Pharma, Jubilant Therapeutics, Juno Therapeutics, Kadmon Pharmaceuticals, Kaken Pharmaceutical, Kalbe Genexine Biologics, Kaleido Biosciences, Kalthera, Kalytera Therapeutics, Kamada, Karate Health, Karolinska Institute, Karyopharm Therapeutics, KBI BioPharma, KBP BioSciences, Kedrion Biopharma, Kennedy Trust For Rheumatology Research, Kiadis Pharma, Kimberly-Clark, Kineta, King's College Hospital, Kings College London, Kiniksa Pharmaceuticals, Kissei Pharmaceutical, Kite Pharma, Klaria, Knight Therapeutics, Kobe University, Kuros Biosciences, KYE Pharmaceuticals, Kymab, Kyma Therapeutics, Kymera Therapeutics, Kyverna Therapeutics, LabGenius, La Jolla Institute for Allergy & Immunology, Lannett, Laurel Venture Capital, Lead Discovery Center, Lead Pharma, Leads Biolabs, LegoChem Biosciences, Leiden University, Leidos, LEO Pharma, Les Laboratoires Servier, Leukemia & Lymphoma Society, LG Life Sciences, LifeArc, LifeMax Laboratories, Ligand Pharmaceuticals, Liminal BioSciences, Lincoln Diagnostics, Lipum, LNC, LogicBio Therapeutics, Lonza, Lorna Linda University, LTL Pharma, Lubeck Institute of Experimental Dermatology, Luminary Therapeutics, Luminex, Lumiphore, Lundbeck, Lund University, Lupin, Lupus Foundation of America (LFA), Lupus Research Alliance, Lupus Research Institute, Lupus Therapeutics, Lurie Children's Hospital of Chicago, Luye Pharma Group, Lynk Pharmaceuticals, MaaT Pharma, MAB Discovery, Mablife, mAbXience, Macrogenics, Macrophage Pharma, Magenta Therapeutics, Magnetic Insight, Mallinckrodt Pharmaceuticals, Marinomed Biotechnologie, Maruho, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, Max-Planck, Maxcyte, Mayo Clinic, McGill University, MD Anderson Cancer Center, MD Biosciences, Medac, Medentech, Medical Research Council, Medical University of South Carolina, Medical University of Vienna, Medical University South Carolina, Medidata Solutions, MediGene, MedImmune, Mediolanum, Medsenic, Meiji Seika, Memorial Sloan Kettering Cancer Center, Merck and Co, Merck KGaA, Merck Sharpe & Dohme, Meritage Pharma, Merus, Mesoblast, Metrion Biosciences, MGC Pharma, Microba Life Sciences, Microbio Shanghai, Microdrop, Micro Labs, Microsoft, MIGAL Galilee Research Institute, MilliporeSigma, Minaris Regenerative Medicine, MIODx, Miravo Healthcare, MISTR, Mitra Biotech, Mitsubishi Tanabe Pharma, Moderna Therapeutics, ModiQuest Research, Momenta Pharmaceuticals, Monash University, Morphic Therapeutic, MorphoSys, Mor Research Applications, Mount Sinai Health System, Mount Sinai Medical Center, Mundipharma, Mustang Bio, My Brother’s Keeper, Mylan Pharmaceuticals, Mytide Therapeutics, NanoPass Technologies, NanoView Biosciences, Napo Pharmaceuticals, NASA, National Cancer Institute, National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Dental and Craniofacial Research (NIDCR), National Institute of General Medical Sciences, National Institutes of Health, National Organization for Rare Disorders, National Research Council Canada, National Science Foundation, National University of Singapore, Nature Technology, Nektar Therapeutics, Neostell, Neovacs, Neovii Pharmaceuticals, NeoX Biotech, Neptune Technologies & Bioressources, Nestle Health Science, NeuCen BioMed, Neukio Biotherapeutics, NeuroCycle Therapeutics, Newsoara Biopharma, New Wave Ventures, New York Medical College, New York University, Neximmune, NextCure, Nexvet, Nichi-Iko Pharmaceutical Co, Nicoya, Nimbus Therapeutics, Ningbo Tai Kang Medical Technology, NJCTTQ, NLC Pharma, Noga Therapeutics, North Carolina State University, Northwestern University, Novadiscovery, Novalere, Novant Health, Novartis, Novelty Nobility, Noveome Biotherapeutics, NovImmune, Novo Nordisk, Novus Therapeutics, NTC, Nuance Pharma, Nuevolution, Numab, Nurix, NYU Langone Medical Center, Oak Hill Bio, Oblique Therapeutics, Ocata Therapeutics, Oklahoma Medical Research Foundation, Olimmune, Omega Therapeutics, Omeros, OncoArendi Therapeutics, OncoImmune, Oncologie, OncoQuest, OncoSec Medical, Onegevity, Oneness Biotech, oNKo-innate, Ono Pharmaceutical, Optimeos Life Sciences, Orange Grove Bio, OraSure Technologies, Orca Pharmaceuticals, Orchard Therapeutics, Orebro University, Orexia Therapeutics, Orexo, Orifarm, Ortho-Clinical Diagnostics, Osaka University, OSE Immunotherapeutics, Oslo University Hospital, Ospedale San Raffaele, Ossium Health, Otsuka, Outpace Bio, Owlstone Medical, Padlock Therapeutics, Palisade Bio, Pandion Therapeutics, Panorama Research, Panther Biotechnology, PANTHERx Specialty Pharmacy, Parvus Therapeutics, PathAI, Pathios Therapeutics, PatientsLikeMe, Peak Bio, Peking University, Pelican Therapeutics, Penn State College of Medicine, PeptiDream, Perelman School of Medicine, Pfizer, Phanes Therapeutics, PharmAkea Therapeutics, Pharming Group, Pharnext, Phebra, Philogen, Phio Pharmaceuticals, PhoreMost, PhosImmune, Pieris, Pierre Fabre, Pinnacle Clinical Research Center, Pionyr Immunotherapeutics, Plan France Relance, Plasticell, Plexision, Pluristem Therapeutics, Pneuma Respiratory, Potenza Therapeutics, PPD, Precision BioSciences, Precision for Medicine, PredictImmune, PreventionGenetics, Principia Biopharma, ProBioGen, ProciseDx, Progentec Diagnostics, Project Inform, Promethera Biosciences, Prometheus Biosciences, Prometheus Laboratories, Prosonix, Protagen, Prota Therapeutics, Proteona, ProThera, ProtoKinetix, Provention Bio, ProvideGx, Provider Network of America, Psilocin Pharma, Pulmatrix, Purdue Pharma, Pure Biologics, PureTech Health, Pyramid Biosciences, Pyxis Oncology, Q2 Solutions, Q32 Bio, Qiagen, Quanticel Pharmaceuticals, Quartet Medicine, Queensland Institute of Medical Research (QIMR), Quell Therapeutics, Quest PharmaTech, R-Pharm, Ragon Institute, Ra Pharmaceuticals, ReAlta Life Sciences, Recipharm, Recordati, RedHill Biopharma, Regado Biosciences, Regeneron Genetics Center, Regeneron Pharmaceuticals, Reign Resources, Remix Therapeutics, Repertoire Genesis, Repertoire Immune Medicines, Repurpose.AI, Research Foundation to Cure AIDS, RespiVert, Revelation Biosciences, ReveraGen BioPharma, Reviva Pharmaceuticals, Revive Therapeutics, Revolo Biotherapeutics, Rexgenero, Rheonix, Rheos Medicines, Richard King Mellon Foundation, Rigel Pharmaceuticals, Rigontec, RIKEN Research Institute, River Vision Development, RMX Biopharma, Roche, Roivant Sciences, Roxall, Ryvu Therapeutics, S.L.E. Lupus Foundation, SAB Biotherapeutics, Salix Pharmaceuticals, Samsung Bioepis, Sanford Burnham Institute, Sanofi, Santhera Pharmaceuticals, Saol Therapeutics, Sartorius Stedim Biotech, SATT Lutech, Schreiner Group, Schrodinger, SciCann Therapeutics, Science Exchange, Scienion, Sciex, Scleroderma Research Foundation, Scopus BioPharma, Scripps Research Institute, Seagen, Seattle Children's Hospital, Seattle Childrens Research Institute, Seattle Genetics, Second Genome, SecondWave Systems, Sedec Therapeutics, Sekris Biomedical, Selecta Biosciences, Selecxine, Selexis, Selvita, Sementis, Sengenics, Senti Biosciences, SenzaGen, Seqirus, Sequenta, Serametrix, SeraNovo, Seres Therapeutics, Sevion Therapeutics, Shandong Fontacea Pharmaceutical, Shanghai Model Organisms Center, Shattuck Labs, Shineco, Shire Laboratories, Shire Pharmaceuticals, Sigyn Therapeutics, Silence Therapeutics, Simbec Research, Simcere Pharmaceuticals, Singota Solutions, Siolta Therapeutics, Sitryx, Skyhawk Therapeutics, Solarea Bio, SomaLogic, Sonora Quest Laboratories, Sorrento Therapeutics, Sosei Heptares, Spring Bank Pharmaceuticals, SQI Diagnostics, St. Jude Children's Research Hospital, STADA Arzneimittel, Stallargenes, Stallergenes Greer, Stanford University, Stanford University School of Medicine, Stellar Biotechnologies, Stony Brook University, Sunshine Infusion Services, SuppreMol, Sutro Biopharma, Swedish Orphan Biovitrum, Swiss Commission for Technology and Innovation, Swixx Biopharma, Sygnature Discovery, Symbiotix Biotherapies, Symphogen, Syndax Pharmaceuticals, Synedgen, Synthekine, Synthorx, Syntimmune, T-Cell Protect Hellas, Takeda Pharmaceutical, Takeda Ventures, Talent Biotech, Tango Therapeutics, Targeted Medical Pharma, Tavotek Biotherapeutics, Teijin, Tel Aviv Sourasky Medical Center, Telix Pharmaceuticals, TeneoBio, Tennessee Hemophilia, Terumo Blood and Cell Technologies, Tessa Therapeutics, Tetra Bio-Pharma, Tetragenetics, Teva Pharmaceutical Industries, The Elizabeth Taylor AIDS Foundation, The Hospital for Sick Children, The Innovation Fund, The International AIDS Vaccine Initiative, The Parker Institute For Cancer Immunotherapy, Theradiag, Therakos, Therapix Bio, Theravance Biopharma, Thermo Fisher Scientific, Thomas Jefferson University, Thorne Research, Thunderbolt Pharma, Tidal Therapeutics, Tikomed, Tiziana Life Sciences, Tizona Therapeutics, T Med, Tmunity Therapeutics, Tobira Therapeutics, Todos Medical, Topas Therapeutics, Torque Therapeutics, Tow Foundation, Traaser, TransBio, Transgene, Transimmune, TransThera, TRexBio, TrialSpark, Trillium Therapeutics, Triumvira Immunologics, True Diagnostics, True North Therapeutics, Tsinghua University, Tufts Medical Center, Turgut Ilaclari, Twist Bioscience, TxCell, Ubiquigent, UCB, Ultimovacs, UMF, Unilife, University College London, University Health Network, University of Alberta, University of Amsterdam, University of Arizona, University of Birmingham, University of British Columbia, University of Calgary, University of California, San Diego, University of California Berkeley, University of California Los Angeles, University of California San Francisco, University of Cambridge, University of Chicago, University of Cincinnati, University of Connecticut, University of Debrecen, University of Dundee, University of Edinburgh, University of Erlangen, University of Florida, University of Geneva, University of Georgia, University of Houston, University of Kiel, University of KwaZulu-Natal, University of Lethbridge, University of Manchester, University of Maryland, University of Maryland School of Medicine, University of Massachusetts, University of Massachusetts Medical School, University of Michigan, University of Minnesota, University of Montreal, University of Natural Resources and Life Sciences, University of New South Wales, University of North Texas Health Science Center, University of Pennsylvania, University of Pittsburgh, University of Queensland, University of Sheffield, University of Texas Southwestern Medical Center, University of Toronto, University of Utah, University of Verona, University of Virginia, University of Western Ontario, University of West Indies, University of Wisconsin-Madison, University of Zurich, Uppsalagruppen Medical, Upsher-Smith, Vaccitech, ValenzaBio, Valneva, Valo Health, Vanderbilt University, Variant Pharmaceuticals, Vaxxinity, VBL Therapeutics (dba), Vedanta Biosciences, Velocity Fund Partners, Velocity Pharmaceutical Development, Ventus Therapeutics, Verily, ViaMune, Viela Bio, Vifor-Fresenius Medical Care Renal Pharma Ltd, Vimian Group, Vinnova, Viome, Vipergen, Vitaeris, Vital Therapies, Vitesse Biologics, Vium, Vividion Therapeutics, Vivoryon Therapeutics, Voluntis, Voronoi, vTv Therapeutics, Vycellix, VYNE Therapeutics, Washington State University, Watson Laboratories, Weill Cornell Medical College, Wellcome Trust Sanger Institute, WellGen, Whitehead Institute, Willow Biosciences, Windgap Medical, Wisconsin Alumni Research Foundation, Worldwide Clinical Trials, Wuhan Kindstar Diagnostics, WuXi Biologics, WuXi NextCODE Genomics, Wyss Institute, X-chem, X4 Pharmaceuticals, Xencor, Xilio Therapeutics, XL-Protein, Xoma, XtalPi, XTL Biopharmaceuticals, Y-Biologics, Yale University, Yangtze River Pharmaceutical Group, Yeda Research and Development Company, Yisheng Biopharma, Yissum Research Development, ZAI Laboratory, Zealand Pharma, Zebra Biologics, Zenas BioPharma, Zenoaq, Zenyaku Kogyo, Ziopharm Oncology, Zyla Life Sciences, Zylo Therapeutics, Zymeworks, ZyVersa Therapeutics
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Collaborative R&D
• Contract service
• Equity purchase
• Joint venture
• Royalty financing
• Spin out
• Sub license
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.